Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eccMIR144/451C is a synthetic extrachromosomal circular DNA (eccDNA) carrying the hsa-mir-144/451 cluster [Sa1212]. Developed by researchers at Peking University, it is designed to suppress innate immune activation in chronic atrophic gastritis (CAG) and prevent its progression to gastric cancer [Sa1212]. Synthesized using the GALA method, eccMIR144/451C is efficiently transcribed to produce precursor miRNAs, leading to elevated levels of miR-4732-5p [Sa1212]. This miRNA directly targets and downregulates 2'-5'-oligoadenylate synthetase-like protein (OASL), thereby suppressing downstream interferon-stimulated genes (such as ISG15, MX2, and IFIT1) and inhibiting cell proliferation while increasing alkaline phosphatase activity [Sa1212].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eccMIR144/451C.
Work on eccMIR144/451C? Claim this page to correct or add information. Claim this page